pbsv_8k.htm
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 or
15(d) OF THE
SECURITIES EXCHANGE
ACT OF 1934
Date of report
(Date of earliest event reported): September 14,
2018
Pharma-Bio
Serv, Inc.
(Exact Name of
Registrant as Specified in Its Charter)
Delaware
(State or Other
Jurisdiction of Incorporation)
|
0-50956
|
20-0653570
|
|
(Commission File
Number)
|
(I.R.S. Employer
Identification No.)
|
|
6 Road 696, Dorado,
Puerto Rico
|
00646
|
|
(Address of
Principal Executive Offices)
|
(Zip
Code)
|
|
(787)
278-2709
|
|
(Registrant’s
Telephone Number, Including Area Code)
|
|
|
|
(Former Name or
Former Address, if Changed Since Last Report)
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b2 of the Securities Exchange Act of 1934
(17 CFR §240.12b2).
Emerging growth
company ☐
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
Results of Operations and Financial Condition
On September 14,
2018, Pharma-Bio Serv, Inc. (the “Company”) issued a
press release announcing its results of operations for the quarter
ended July 31, 2018. A copy of the press release is furnished as
Exhibit 99.1 to this report
The information
furnished pursuant to this Item 2.02, including
Exhibit 99.1, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject
to the liabilities under that section and shall not be deemed to be
incorporated by reference into any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such
filing.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit
No.
|
|
Description
|
|
|
|
|
|
|
|
Press Release,
dated September 14, 2018
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
PHARMA-BIO SERV,
INC.
|
|
|
|
|
|
|
|
Date: September 14,
2018
|
By:
|
/s/ Pedro J.
Lasanta
|
|
|
|
|
Pedro J.
Lasanta
|
|
|
|
|
Chief Financial
Officer, Vice President Finance and Administration and
Secretary
|
|
|
|
|
|
|
3